Pipeline

Traverse Biotech has a growing pipeline of cutting-edge immunotherapies with the potential to treat some of the most challenging diseases. We are developing these highly differentiated products that are derived from clinically validated therapeutic platforms.

CD3 X ROR2 DuoBodyTM in Multiple Oncology Indications Oncology Image
Targeting Innate Immunity in Oncology and Aging
Additional Technologies

TB-Bs1

TB-UA-1

TB-NOD-2

R&D

Research & Development

Preclinical

CD3 X ROR2 DuoBody® in ROR2+ Oncology Indications

ADC in undisclosed indications                                   

Stimulate innate immunity in oncology and neurodegeneration

In-situ therapy platform

IND-enabling

Phase I/II

Partner

More on the Science behind our Lead Product

ROR2 as a T Cell Engager Target

ROR2 is an attractive novel target linked to tumor-dependent pathways and processes

  • Expressed during embryonic development.

  • Reappears during cancer development

  • Activates multiple pro-tumor pathways

Relevant publications on ROR2:

  1. Debebe et al., "Ror2 as a therapeutic target in cancer," Pharmacology & therapeutics (2015).

  2. Babin et al., “De novo generation of the NPM-ALK fusion recapitulates the pleiotropic phenotypes of ALK+ ALCL pathogenesis and reveals the ROR2 receptor as a target for cancer cells,” Mol Cancer (2022).

  3. Grither, Whitney R., et al. "ROR2/Wnt5a signaling regulates directional cell migration and early tumor cell invasion in ovarian cancer." Molecular Cancer Research (2024).

  4. Roarty K, Pfefferle AD, Creighton CJ, Perou CM, Rosen JM. Ror2-mediated alternative Wnt signaling regulates cell fate and adhesion during mammary tumor progression. Oncogene. 2017 Oct;36(43):5958-68.

Read more about the Duobody platform here.